Shots:
- BMS to get non-exclusive access to Xencor’s Xtend Fc technology to extend the half-life of a novel Ab combination therapy that is intended to neutralize the SARS-CoV-2 virus to prevent COVID-19
- BMS will solely lead research, development, regulatory and commercial activities for SARS-CoV-2 mAb Duo. Xencor is eligible to receive royalties from the sales of products including Abs
- P-I study will assess dosing and safety of the SARS-CoV-2 mAb Duo, discovered by investigators at Rockefeller University Hospital, while the P-II & P-III studies are being planned as part of the NIH ACTIV-2 trial examining the treatment of infected outpatients
Click here to read full press release/ article | Ref: Businesswire | Image: Xencor
The post BMS and Xencor Collaborate to Use Xtend XmAb Technology in SARS-CoV-2 Neutralizing mAb Combination for COVID-19 first appeared on PharmaShots.
